Vertice Pharma is a specialty branded and generic pharmaceuticals platform focused on acquiring specialty pharmaceuticals companies and products to create a durable specialty pharmaceutical platform of scale. Vertice Pharma was formed in 2015 by Warburg Pincus and senior pharmaceutical executive Don DeGolyer, former COO of Endo International plc and CEO of North America for Sandoz International GmbH. In late 2015, Warburg Pincus helped Vertice Pharma acquire VistaPharm, Inc., a Tampa, Florida-based specialty generics manufacturer of liquid and unit dosage medications focused on the hospital channel. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Providence, New Jersey.
Warburg Pincus is a leading global private equity firm focused on thesis-driven growth investing at scale. With more than $54 billion in assets under management, our active portfolio of more than 185 companies is highly diversified by stage, sector and geography. As an experienced partner to outstanding management teams, we help build durable companies with sustainable value. We have raised 19 private equity funds, which have invested more than $83 billion in over 895 companies in more than 40 countries.